You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 202181 - 202190 of 207699 results
  1. Near Patient Acute Kidney Injury Biomarker Analysis in Critically Ill Neonates

    SBC: BAEBIES, INC.            Topic: NICHD

    Acute kidney injury (AKI) contributes to mortality and morbidity in critically ill neonates. The identification and treatment of AKI are currently based on serum creatinine (sCr) levels; however, mounting evidence suggests that sCr alone is insufficient to predict or prevent renal injury. sCr is in fact a measure of renal function, not injury; sCr levels usually rise many hours after a renal injur ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. 3D-Printed Superhydrophobic-Tipped Optical Fiber for Targeted Periodontal Photodynamic Therapy

    SBC: SINGLETO2 THERAPEUTICS LLC            Topic: NIDCR

    Eradication of bacteria located in periodontal pockets presents a daunting challenge to dentists and oral care professionals. The problem is significant; severe periodontitis is the 6th most prevalent disease worldwide with over 743 million people affected. The global cost of lost productivity from severe periodontitis is estimated to be $54 billion USD/year. Antibiotics with scaling and root plan ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Robust, defined, animal-free cell culture medium for the production of vaccines

    SBC: VENTRIA BIOSCIENCE            Topic: NIAID

    DESCRIPTION (provided by applicant): The Vero cell line is used in the production of viral based vaccines. The use of cell based vaccines based on the Vero cell line is growing. The majority of the vaccines in use today are produced using cell culture medium supplemented with serum. The use of animal-derived products in vaccine culture media presents a risk for the transmission of infectious disea ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  4. Neurxtem Neural Organoid Human Platform Development for Substance and Opioid Use Disorders

    SBC: Neurxstem, Inc.            Topic: NIDA

    This is a SBIR proposal from Neurxstem Inc., a company selected by NCET2 as a “Best University Startups 2016” is in response to the NIH HEAL initiative. Neurxstem’s goals are to develop and optimize a proprietary induced pluripotent stem cell derived human Neural Organoid Platform (NNOP) to develop 1) an early diagnostic NNOP for substance (SUD) and opioid (OUD) use disorder susceptibility a ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  5. 3D Acoustic Model for Geometrically Constrained Environments

    SBC: HEAT, LIGHT, AND SOUND RESEARCH, INC.            Topic: N16AT018

    The goal of this work is to demonstrate and validate a 3D acoustic propagation model for use in constrained environments such as harbors. The 3D model will be used to model system performance for 1) passive sonar, 2) active sonar, and 3) acoustic communications networks. This latter application is of primary importance in this Phase II Extended proposal. To accomplish these goals are sequence of f ...

    STTR Phase II 2023 Department of DefenseNavy
  6. Cryo-EM Grid Screening Tool

    SBC: Gregory Hirsch            Topic: C5327a

    C53-27a-271143Transformative advances in cryogenic electron microscopy (cryo-EM) have expanded our ability to visualize cellular and biomolecular structure, often at atomic resolution. However, a significant hurdle for achieving the full potential of cryo-EM, including work performed at facilities associated with DOE, involves difficulties with sample preparation. Reliably producing vitrified ultr ...

    SBIR Phase II 2023 Department of Energy
  7. Volume Charge Distribution Measurement in Thin Dielectrics

    SBC: BOX ELDER INNOVATIONS LLC            Topic: AF11BT20

    ABSTRACT:Over half of spacecraft system anomalies attributed to interactions with the natural space environment including - electron upsets, damage to components, power system debilities, and complete satellite failures - are attributed to spacecraft charging.While measurements of electron emission, surface potential, and electrostatic breakdown provide important information, the great need for ma ...

    STTR Phase II 2013 Department of DefenseAir Force
  8. A NEW MECHANISM FOR TREATING OBESITY

    SBC: FGH BIOTECH, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant The Specific Aim of this proposal is to file an IND to allow for a Phase I clinical safety study of FGH with an indication for the control of obesity We successfully met the primary endpoints of our SBIR Phase I study R HL As shown by the Phase I report of this proposal following oral gavage significant control of weight gain and improvement ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  9. MEASUREMENT OF HIV PROTEASE INHIBITORS IN PATIENT SERA

    SBC: NORZYME, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): During phase I the feasibility of a test kit for the fluorometric measurement of HIV protease inhibitors (PI) in human serum has been demonstrated. The overall objective of this phase II investigation is the development of a robust fluorometric diagnostic test kit, trade name Levoprin-ZG, for clinical laboratories, to be used for therapeutic dose monitoring (T ...

    SBIR Phase II 2002 Department of Health and Human ServicesNational Institutes of Health
  10. Potent Antifolates as New Therapeutics for MRSA

    SBC: Promiliad Biopharma Incorporated            Topic: NIAID

    DESCRIPTION (provided by applicant): This Phase II STTR proposal describes a collaborative effort between researchers in the Department of Pharmaceutical Sciences at the University of Connecticut and Promiliad Biopharma to develop efficacious antibiotics targeting both methicillin-resistant strains of Staphylococcus aureus (MRSA) and Streptococcus pyogenes. We have recently completed a Phase I STT ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government